The treatment, which isn’t specifically designed for treating opioid addiction, is anticipated to be accessible in August.
The FDA (Food and Drug Administration) has permitted the first non-opioid treatment to assist the adult in dealing with the withdrawal symptoms of Opioid. In the meantime, the agency is continuously developing the alternative options to help individuals suffering from opioid addiction.
Scott Gottlieb, Commissioner, FDA said, “We are creating new guidelines to help increase the pace of developing better alternative treatments, including the ones which help in managing withdrawal symptoms of opioid. He further added, “We are aware that the physical withdrawal symptoms can be the biggest issues for which the patient needs assistance and medical help.”
The sanctioning of Lucemyra brings along the filed lawsuits from 20+ states and hundreds of counties and cities against the manufacturers and distributors of opioid-painkillers, accusing that they powered a crisis by misrepresenting the risks related to drugs. Some of the companies proactively denied the allegations.
Lucemyra usually referred as lofexidine hydrochloride, is an oral medication which helps in reducing the release of norepinephrine, which has the key role in developing the withdrawal symptoms like agitation, anxiety, muscle pain, sleep disorders, and nausea, mentioned by the agency. Individuals can experience the symptoms by reducing and stopping the opioids consumption.
The non-opioid drug has some common side-effects such as slow heart rate, low blood pressure, dizziness, sleep disorder etc. The drug is also related to the case of an increase in the abnormal heart rate and few cases of fainting. The FDA said, “When patients stop using the non-opioid drug, they can experience a noticeable increase in blood pressure.”
However, Lucemyra is effective in reducing the rigorousness of withdrawal symptoms; it cannot cure them completely, as said by the FDA. This drug is only approved by the agency for treatment up to 2 weeks.